For the year ending 2025-12-31, NBY has $9,035K in assets. $31,861K in debts. $7,958K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 7,958 | |||
| Prepaid expenses and other current assets | 717 | |||
| Current assets, discontinued operations | 0 | |||
| Total current assets | 8,675 | |||
| Operating lease right-of-use assets | 0 | |||
| Other assets | 360 | |||
| Other assets, discontinued operations | 0 | |||
| Total assets | 9,035 | |||
| Accounts payable | 257 | |||
| Accrued liabilities | 396 | |||
| Bridge loan | 0 | |||
| Unsecured convertible notes, net of discounts | 67 | |||
| Operating lease liabilities | 422 | |||
| Current liabilities, discontinued operations | 0 | |||
| Total current liabilities | 1,142 | |||
| Warrant liabilities, at fair value | 30,432 | |||
| Operating lease liabilities-non-current | 287 | |||
| Total liabilities | 31,861 | |||
| Preferred stock, 0.01 par value 5,000 shares authorized series f preferred stock 1,347 and 0 shares issued and outstanding at december 31, 2025 and 2024, respectively | 350 | |||
| Preferred stock, value, issued-Series BPreferred Stock | 6 | |||
| Common stock, 0.01 par value 1,500,000 shares authorized, 25,216 and 977 shares issued and outstanding at december 31, 2025 and 2024, respectively-Series DPreferred Stock | 252 | |||
| Additional paid-in capital | 186,981 | |||
| Accumulated deficit | -210,415 | |||
| Total stockholders (deficit) | -23,176 | |||
| Total liabilities and stockholders deficit | 9,035 | |||
NovaBay Pharmaceuticals, Inc. (NBY)
NovaBay Pharmaceuticals, Inc. (NBY)